Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


22nd Annual H.C. Wainwright Global Investor Conference presentation at1:30 p.m. ET on September 16TH


GlobeNewswire Inc | Sep 8, 2020 08:00AM EDT

September 08, 2020

22nd Annual H.C. Wainwright Global Investor Conference presentation at1:30 p.m. ET on September 16TH

Oppenheimer Fall Healthcare LifeSciences & Medtech Summit Fireside Chat at 10:00 a.m. ET on September 23RD

PITTSBURGH, Sept. 08, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (NeuBase or the Company), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the virtual H.C. Wainwright 22nd Annual Global Investment Conference, as well as participate in a fireside chat at the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, which are both being held in September 2020.

Conference Details:Event: H.C. Wainwright 22^nd Annual Global Investment Conference (virtual)Format: PresentationDate: Wednesday, September 16^THTime: 1:30 p.m. ETLocation: Webcast Link - or at the company?s website (click here) Event: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (virtual)Format: Fireside ChatDate: Wednesday, September 23^RDTime: 10:00 a.m. ETLocation: Webcast Link - or at the company?s website (click here)

About NeuBase TherapeuticsNeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBases designer PATrOL therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.

NeuBase Investor Contact: Dan Ferry Managing Director LifeSci Advisors, LLCDaniel@lifesciadvisors.com OP: (617) 430-7576

NeuBase Media Contact: Cait Williamson, Ph.D.LifeSci Public Relationscait@lifescipublicrelations.comOP: (646) 751-4366









Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC